Rahul Mathur
Analyst · ROTH Capital. You may now ask your question
Thanks, Luc. I'd like to begin with our financial results for the third quarter. Let me start with some highlights on slide five. As Luc mentioned, we delivered a solid quarter. We delivered financial results in line with our revenue expectations and at the high-end of our earnings expectations, while continuing to strengthen our balance sheet and make progress on a number of business initiatives, as well as our long-term growth strategy. We've adopted ASC 606 in 2018 using the modified retrospective method, which did not restate prior periods, but rather runs the cumulative effect of the adoption through retained earnings as a beginning balance sheet adjustment. Any comparison between our results under ASC 606 and prior results under ASC 605 is not an accurate way to track our company's progress. We will continue to provide operational metrics, such as licensing billings to give our investors better insight into our operational performance. We delivered revenue of $56.9 million and licensing billings of $53.1 million in line with our expectations. The strength of our model reflects our proved record of generating strong cash flows. We have a very strong balance sheet and ended the quarter with cash, cash equivalents and marketable securities of $520.2 million up nicely from the previous quarter, primarily due to cash from operations of $44.1 million. This brings year-to-date cash from operations for the nine months to $143.4 million, well above last year's full year total of $128.5 million, with another quarter remaining in the current year. Our continued execution on our strategy and our operational discipline have yielded solid financial results and a strong balance sheet that affords us flexibility to support our strategic initiatives. Over the past years, growth in our product businesses has enabled us to offset the known step-downs in patent licensing. We are well-positioned for next year with our final significant licensing step-down scheduled for Q4. Our products will drive overall company growth in 2021, improving both our top and bottom line. Now let me talk you through some revenue details on slide six. Revenue for the third quarter was $56.9 million in line with our expected range. Royalty revenue for the third quarter was $16.6 million, while licensing billings was $63.1 million. The difference between licensing billings and royalty revenue primarily relates to timing as we don't always recognize revenue in the same quarter as we bill our customers. Going into additional detail, our product revenue was $29.8 million, consisting primarily of our buffer chip business. Our contract and other revenue was $10.5 million, consisting primarily of our Silicon IP business. For the year, there's roughly $40 million of our Silicon IP business that's being reflected in our licensing billings. This is almost twice what we expected at our Analyst Day a year ago. Strength in our security IP business, in particular enabled us to meet our revenue expectations in Q3. These results represent excellent growth year-over-year. Let me now walk you through our non-GAAP income statement on slide seven. Along with our revenue performance in Q3, we again exceeded our profitability targets as we have done consistently over the past many years. Total operating expenses, including COGS for the quarter came in at $56.7 million. Operating expenses of $45.8 million were lower than in the prior quarter due to lower expenses related to our headquarter facility and other variable expenses. Multiple revenue streams enabled us to offset quarterly variances in any particular business. We ended the quarter with headcount of 679, slightly hither than 670 in the previous quarter as we continue to invest in our product program. Under ASC 606, we recorded $3.3 million of interest income related to the financing component of our fixed fee licensing arrangement for which we have recognized revenue, but not yet received payment. We incurred $0.8 million of interest expense primarily associated with our convertible notes. This was offset by incremental interest income related to the return on our cash and investment portfolio. After adjusting for non-cash interest expense on a convertible note, this resulted in non-GAAP interest and other income for the quarter of $2.7 million. Excluding the interest income related to the significant financing component related to ASC 606, this would have been $0.6 million of interest and other expense. Assuming a flat rate of 24% for non-GAAP pretax income, non-GAAP net income for the quarter was $2.2 million. With continued focus on cost and disciplined execution, we delivered profit that was nicely above our expectations. Now let me turn to the balance sheet details on slide eight. Over the past several years, we've built a very strong balance sheet. Cash, cash equivalents and marketable securities totaled $520.2 million, up significantly from the previous quarter, primarily through cash from operations of $44.1 million. As I mentioned previously, year-to-date cash from operations for the nine months was $143.4 million, well above last year's total of $128.5 million with another quarter remaining in the current year. As we continue to deliver on the top line and execute on operational efficiency, we expect to continue to deliver strong cash from operations into the future. At the end of Q3, we had contract assets worth $401.7 million, which reflects the net present value of unbilled AR related to licensing arrangements for which the company has no future performance obligations. I expect this number to continue to trend down as we bill and collect for these contracts. It's important to note that this metric doesn't represent the entire value of our existing licensing agreements as several customers have royalty-based agreements that allow us to recognize revenue each quarter under ASC 606. As we announced previously, we were pleased to extend our existing licensing agreement with Micron in September at our existing financial terms, demonstrating the strength and relevance of our patent portfolio. When this extension comes into effect in Q4, we expect to account for this agreement to be recognized as a variable contract. We do not expect one-time impact to revenue nor the corresponding addition to our unbilled contract assets. Instead, we expect to recognize ASC 606 revenue on a quarterly basis starting in the first quarter of 2021. Between this extension and buffer chip growth, our ASC 606 revenue is poised for strong growth next year. From a licensing billings perspective, as negotiated in the original agreement, the Micron contract will step-down to $4.5 million in Q4 and then step back up to $10 million in the quarter from Q1 2021 through Q4 of 2024. It's also worth noting, we renewed our agreement for four years longer than the extension period initially specified. We have a strong partnership with Micron and this bodes well for our upcoming renewals and extensions with our other partners. Over time, we endeavor to transition renewals and extensions to variable agreements that could allow us to take revenue over time as opposed to upfront under ASC 606. Third quarter CapEx was $10.6 million and depreciation was $4.8 million. We delivered $33.5 million of free cash flow in the quarter. Looking forward, I expect roughly $14 million of CapEx for the fourth quarter. This represents roughly $35 million for the full year of 2020, 80% of which is related to the relocation of our headquarters facility. I also expect depreciation of roughly $5 million for the fourth quarter and roughly $19 million for the full year of 2020. Now, let me turn to our guidance for the fourth quarter on slide nine. As a reminder, our forward-looking guidance reflects our current best estimates that our actual results could differ materially from what I'm about to review. In addition to the financial outlook under ASC 606, we've also been providing information on licensing billings, which is an operational metric that reflects amounts invoiced to our licensing customers during the period adjusted for certain differences. As you've see in the supplemental information we provided on slide 13 of our earnings deck, licensing billings closely correlates with what we had historically reported as royalty revenue under ASC 605. Under ASC 606, we expect revenue in the fourth quarter between $45 million and $51 million. We expect royalty revenue between $12 million and $18 million. We also expect licensing billings between $61 million and $67 million. We've been making steady progress on our business and financial initiatives. Similarly, we're very pleased with the execution on the acquisitions we made last year. The teams have integrated well into our company and on a trajectory nearing our expectations at the time of each acquisition. Our guidance reflects the contract terms of the patent licensing potential with Micron, I mentioned previously, as well as the inventory digestion impacting our buffer chip business. As we've been discussing, we've been monitoring the inventory build we saw at the beginning of the year, and we're confident this pause doesn't reflect any change in our competitive position or market share. As Luc mentioned, we expect to be through this in early 2021. Our Q4 guidance on buffer chip reflects annual growth of over 50% year-over-year and is almost 30% better than what we anticipated at last year's Analyst Day. In total, our Q4 guidance reflects financial results for 2020 that are substantially better than what we expected at last year's Analyst Day on both the top and bottom line, despite the unprecedented challenges presented by COVID-19. We expect Q4 non-GAAP total operating costs and expenses, which include COGS, to be between $59 million and $55 million as we continue to invest in programs. Under ASC 606, non-GAAP operating results for the fourth quarter are expected to be between $4 million and a $14 million loss. For non-GAAP interest and other income and expense, which excludes interest income related to ASC 606, we expect this to be approximately $1 million of expense, which includes $0.6 million of interest expense related to the notes due in 2023. We expect our pro forma tax rate in 2020 to remain consistent with our 2019 pro forma tax rate of roughly 24%. The 24% is higher than the statutory rate of 21%, primarily due to higher tax rates in our foreign jurisdictions. As a reminder, we paid roughly $20 million of cash taxes each year, driven primarily by our licensing agreements with our partners in Korea. We expect non-GAAP taxes to be between a benefit of $1 million and $4 million in Q4. We expect our Q4 share count to be roughly 117 million basic and diluted shares outstanding. This leads you to between a non-GAAP loss per share of $0.03 and $0.10 for the quarter. We have gone through a successful transformation over the past several years and our strong product growth has offset structural step-downs in patent licensing, the divestiture of payments and ticketing and the shutdown of our lighting business. This has resulted in the roughly flat top line, as we transition back to our core semiconductor focus. Through this transition however, our operational discipline resulted in fantastic growth in cash from operations. As we look forward, the scheduled step-down of patent licensing will be behind us. And in the coming years, we expect patent licensing to stabilize at the same level we expect to see in 2020. As I mentioned earlier, our product growth will translate into profitable growth in 2021. With that said, while we don't provide guidance beyond Q4, we're comfortable with the analyst consensus estimates at the top line and bottom line for each quarter of 2021. While the near-term macroeconomic conditions are difficult for any of us to predict, consensus estimates are currently in line with our long-term strategy reflecting product growth that continues to be significantly better than the broader semiconductor industry. Our confidence in our long-term prospects is reflected in the new $20 million share repurchase authorization from our Board that we announced earlier today. Let me finish with a summary on slide 10. We are proud of the excellent performance by our team in this unpredictable macroeconomic environment and the progress we continue to make against strategic initiatives to drive long-term profitable growth. While we understand that ASC 606 added a level of complexity to our financial reporting, it's important to reiterate that the underlying financial strength of our business remains strong. We have a predictable base of revenue and a demonstrated ability to generate cash. We have refocused our product portfolio around Rambus' core strength in the semiconductor industry and are well-positioned with a predictable licensing base and multiple product revenue streams across our company. We have continued to execute and our operational discipline has yielded solid cash from operations. We continue to leverage our strong balance sheet to support our strategic initiatives. Before I open up the call to Q&A, I would once again like to thank our employees for their continued teamwork and execution resilience during these uncertain times. Everyone, please stay safe and take care of yourself and your families. With that, I'll turn the call back to our operator to begin Q&A. Could we please have our first question?